Profile data is unavailable for this security.
About the company
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
- Revenue in AUD (TTM)96.30m
- Net income in AUD32.54m
- Incorporated1999
- Employees16.00
- LocationClinuvel Pharmaceuticals LtdLevel 22, 535 Bourke StreetMELBOURNE 3000AustraliaAUS
- Phone+61 39660-4900
- Fax+61 39660-4909
- Websitehttps://www.clinuvel.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 117.56m | 1.00 | -- | 1.28 | -- | 20.42 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Vita Life Sciences Ltd | 93.27m | 10.44m | 146.93m | 124.00 | 14.67 | 2.65 | -- | 1.58 | 0.1833 | 0.1833 | 1.64 | 1.01 | 1.21 | 2.29 | 7.28 | -- | 13.52 | 15.15 | 18.79 | 21.21 | 61.15 | 59.76 | 11.18 | 11.85 | 2.10 | -- | 0.0409 | 57.39 | 17.31 | 14.95 | 18.80 | 11.36 | 44.98 | 26.93 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 150.38m | -- | -- | -- | -- | 19.52 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Starpharma Holdings Ltd | 13.86m | -3.23m | 182.66m | 50.00 | -- | 8.50 | -- | 13.18 | -0.0077 | -0.0077 | 0.0331 | 0.0512 | 0.4968 | 0.6233 | 3.55 | -- | -11.58 | -26.74 | -13.95 | -32.74 | 90.67 | 74.76 | -23.32 | -268.76 | 4.86 | -- | 0.0355 | -- | -49.65 | -5.61 | -22.35 | -- | -19.60 | -- |
| Mayne Pharma Group Ltd | 410.85m | -82.21m | 199.05m | 450.00 | -- | 0.5644 | -- | 0.4845 | -1.04 | -1.05 | 5.18 | 4.34 | 0.3967 | 2.80 | 2.35 | 913,002.30 | -7.94 | -15.32 | -10.90 | -20.87 | 62.98 | 53.04 | -20.01 | -64.51 | 1.14 | -11.97 | 0.1075 | -- | 4.44 | -2.04 | 46.58 | -- | -9.26 | -- |
| Clinuvel Pharmaceuticals Ltd | 96.30m | 32.54m | 502.01m | 16.00 | 15.53 | 2.02 | 14.93 | 5.21 | 0.644 | 0.644 | 1.90 | 4.96 | 0.3807 | 0.5917 | 5.86 | -- | 12.86 | 17.33 | 13.70 | 19.40 | 94.53 | 94.28 | 33.79 | 39.45 | 14.17 | -- | 0.0013 | 7.22 | 7.76 | 23.88 | 1.50 | 19.17 | -19.60 | 14.87 |
| Neuren Pharmaceuticals Ltd | 76.81m | 30.44m | 1.74bn | -- | 59.16 | 5.15 | 57.25 | 22.70 | 0.2328 | 0.2328 | 0.5874 | 2.67 | 0.2041 | -- | 0.7819 | -- | 8.09 | 34.81 | 8.67 | 38.73 | -- | -- | 39.63 | 57.72 | -- | -- | 0.00 | 0.00 | -65.75 | 145.35 | -78.57 | -- | 43.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.54m | 3.06% |
| Vanguard Investments Australia Ltd.as of 31 Jan 2026 | 783.67k | 1.56% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 681.36k | 1.36% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 431.54k | 0.86% |
| DFA Australia Ltd.as of 31 Jan 2026 | 378.04k | 0.75% |
| BlackRock Asset Management North Asia Ltd.as of 31 Oct 2025 | 132.70k | 0.26% |
| Whitefield Capital Management Pty Ltd.as of 31 Mar 2025 | 100.07k | 0.20% |
| Charles Schwab Investment Management, Inc.as of 05 Feb 2026 | 83.86k | 0.17% |
| Macquarie Investment Management Global Ltd.as of 04 Feb 2026 | 57.17k | 0.11% |
| Vanguard Fiduciary Trust Co.as of 31 Jan 2026 | 47.12k | 0.09% |
